5 results match your criteria: "Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai China.[Affiliation]"
Discovery of a non-nucleotide stimulator of interferon genes (STING) agonist with systemic antitumor effect.
MedComm (2020)
January 2025
Agonists of the stimulator of interferon genes (STING) pathway are increasingly being recognized as a promising new approach in the treatment of cancer. Although progress in clinical trials for STING agonists in antitumor applications has been slow, there is still an urgent need for developing new potent STING agonists with versatile potential applications. Herein, we developed and identified a non-nucleotide STING agonist called DW18343.
View Article and Find Full Text PDFArticle Synopsis
- Mitochondria play a crucial role in cell function and are linked to various diseases, leading to the development of targeted imaging and treatment strategies.
- Theranostics combines diagnosis and therapy in a single agent, simplifying treatment and improving drug evaluation by focusing on mitochondria-specific interventions.
- Recent advancements in mitochondria-targeting theranostic materials have been summarized, highlighting their design and effectiveness in localized disease treatment and diagnosis.
From structural design to delivery: mRNA therapeutics for cancer immunotherapy.
Exploration (Beijing)
April 2024
State Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai China.
Article Synopsis
- - mRNA therapeutics are gaining traction in cancer immunotherapy due to their effectiveness in producing a wide range of proteins, including mutant neo-antigens, that can stimulate T cells to fight tumors.
- - Advanced techniques like in vitro transcription allow for the quick synthesis of pure mRNA, but challenges remain in delivering this mRNA to target cells effectively and ensuring it escapes endosomes after delivery.
- - New strategies to improve mRNA cancer therapies focus on modifying mRNA structures and enhancing delivery systems, particularly through lipid nanoparticles, to address current limitations and boost clinical application prospects.
PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1.
MedComm (2020)
April 2023
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research Nankai University Tianjin China.
Protein arginine methyltransferase 5 (PRMT5) is a major type II enzyme responsible for symmetric dimethylation of arginine (SDMA), and plays predominantly roles in human cancers, including in ovarian cancer. However, the exactly roles and underlying mechanisms of PRMT5 contributing to the progression of ovarian cancer mediated by reprogramming cell metabolism remain largely elusive. Here, we report that PRMT5 is highly expressed and correlates with poor survival in ovarian cancer.
View Article and Find Full Text PDFPhloretin (Ph) is a natural active ingredient with wide biological properties. However, its poor water-solubility and low oral bioavailability limit the application significantly in functional food and drug. This study was to explore the mixed polymer Pluronic® F127 and P123 modified the different triglycerides (LCT, MCT, SCT) in self-nanoemulsions (SNEs) for enhancing the oral bioavailability and bioefficacy of Ph.
View Article and Find Full Text PDF